Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2007;115:2076-2086
doi: 10.1161/CIRCULATIONAHA.106.658930
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sosnovik, D. E.
Right arrow Articles by Weissleder, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sosnovik, D. E.
Right arrow Articles by Weissleder, R.
Related Collections
Right arrow Cardiovascular imaging agents/Techniques
Right arrow Animal models of human disease
Right arrow Pathophysiology
Right arrow Imaging
Right arrow CT and MRI
Right arrow Acute myocardial infarction

(Circulation. 2007;115:2076-2086.)
© 2007 American Heart Association, Inc.


New Drugs and Technologies

Molecular Magnetic Resonance Imaging in Cardiovascular Medicine

David E. Sosnovik, MD; Matthias Nahrendorf, MD; Ralph Weissleder, MD, PhD

From the Center for Molecular Imaging Research (D.E.S., M.N., R.W.) and the Department of Cardiology (D.E.S.), Massachusetts General Hospital, Harvard Medical School, Boston, Mass.

Correspondence to David Sosnovik, MD, FACC, Center for Molecular Imaging Research, Massachusetts General Hospital, 149 13th St, Charlestown, MA 02129. E-mail sosnovik@nmr.mgh.harvard.edu


Key Words: atherosclerosis • cardiovascular diseases • magnetic resonance imaging • myocardium • nanotechnology


An extract of the first 250 words of the full text is provided, because this article has no abstract.
 


*    Introduction
 
The ability of magnetic resonance imaging (MRI) to evaluate cardiovascular pathophysiology at several levels is one of the strengths of the technique. As shown in Figure 1, cardiac phenotype can be assessed at the whole-organ level by cine MRI, at the regional level with strain, perfusion, and viability imaging, and at the metabolic level with spectroscopic techniques.1,2 However, MRI of biological processes at the cellular and subcellular level (molecular MRI) has been studied most extensively in other disease states such as cancer.3,4 Molecular MRI techniques are, however, being increasingly developed for cardiovascular applications and, if fully developed, have the potential to make a significant impact on the practice of cardiovascular medicine.


Figure Removed (Available Only in the Full Text)
View larger version (60K):



 
Figure 1. Comprehensive analysis of cardiac phenotype by MRI. A, cine MRI of a mouse heart; B, area of myocardial infarction delineated by delayed enhancement MRI in a mouse heart; C, corresponding triphenyltetrazolium (TTC) image. D, map of myocardial perfusion (ml/g per min) in a mouse heart obtained with a spin labeling technique;1 E, strain rate imaging at the midventricular level in a wild-type mouse;1 F, a phosphocreatine metabolite map in an isolated perfused rat heart fused with the corresponding coronary angiogram.2 Comprehensive imaging of the human heart can be performed with identical techniques. Molecular MRI thus offers the potential for complete anatomic, functional, metabolic, and molecular imaging with a single modality from bench to bedside.

The advantages of an MRI-based approach to molecular imaging reflect the general attributes of the technique. MRI is noninvasive, tomographic, nonionizing, and . . . [Full Text of this Article]




This article has been cited by other articles:


Home page
RadiologyHome page
D. E. Sosnovik
Will Molecular MR Imaging Play a Role in Identification and Treatment of Patients with Vulnerable Atherosclerotic Plaques?
Radiology, May 1, 2009; 251(2): 309 - 310.
[Full Text] [PDF]


Home page
Circ Cardiovasc ImagingHome page
D. E. Sosnovik, R. Wang, G. Dai, T. Wang, E. Aikawa, M. Novikov, A. Rosenzweig, R. J. Gilbert, and V. J. Wedeen
Diffusion Spectrum MRI Tractography Reveals the Presence of a Complex Network of Residual Myofibers in Infarcted Myocardium
Circ Cardiovasc Imaging, May 1, 2009; 2(3): 206 - 212.
[Abstract] [Full Text] [PDF]


Home page
radtechHome page
E. J CHURCH
Imaging Diabetes
Radiol. Technol., March 1, 2009; 80(4): 340 - 360.
[Abstract] [Full Text] [PDF]


Home page
Circ Cardiovasc ImagingHome page
M. Nahrendorf, D. E. Sosnovik, B. A. French, F. K. Swirski, F. Bengel, M. M. Sadeghi, J. R. Lindner, J. C. Wu, D. L. Kraitchman, Z. A. Fayad, et al.
Multimodality Cardiovascular Molecular Imaging, Part II
Circ Cardiovasc Imaging, January 1, 2009; 2(1): 56 - 70.
[Full Text] [PDF]


Home page
CirculationHome page
C. von zur Muhlen, D. von Elverfeldt, J.A. Moeller, R.P. Choudhury, D. Paul, C.E. Hagemeyer, M. Olschewski, A. Becker, I. Neudorfer, N. Bassler, et al.
Magnetic Resonance Imaging Contrast Agent Targeted Toward Activated Platelets Allows In Vivo Detection of Thrombosis and Monitoring of Thrombolysis
Circulation, July 15, 2008; 118(3): 258 - 267.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. Nahrendorf, H. Zhang, S. Hembrador, P. Panizzi, D. E. Sosnovik, E. Aikawa, P. Libby, F. K. Swirski, and R. Weissleder
Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis
Circulation, January 22, 2008; 117(3): 379 - 387.
[Abstract] [Full Text] [PDF]